Hyperhomocysteinemia, paraoxonase activity and risk of coronary artery disease

Objectives: Paraoxonase-1 (PON1) detoxifies homocysteine thiolactone (HcyT) in human blood and could thus delay the development of atherosclerosis. We investigated (a) PON1 activity and polymorphisms, and (b) the relationship between PON1 activity, homocysteine (Hcy) and the severity of CAD patients in Tunisian population. Design and methods: We used PCR-RFLP analysis to detect the Q192R and L55M variants of the PON1 gene in 100 patients with CAD and in 120 healthy controls. Paraoxonase activity was measured spectrophotometrically using phenylacetate as a substrate. Total plasma homocysteine concentrations were determined by direct chemiluminescence assay. Results: We found an increased Hcy level in CAD patients compared to the control group (15.86 ± 8.63 vs. 11.9 ± 3.25 μmol/L respectively, P < 0.001), and a decrease in PON1 activity in CAD patients as compared to the control group (117 ± 56 vs. 181 ± 73 U/mL respectively, P < 0.001). PON1 Q192R and L55M polymorphisms were not associated with the presence of CAD (P = 0.592, P = 0.294, respectively). However, we found that PON1 activity is lower with the PON1 192RR than with PON1 192QQ genotypes in the study population. Furthermore, there were no association between PON1 L55M polymorphism and PON1 activity. We showed a significant decrease in PON1 activity in CAD patients presenting 0- to 3-vessel stenosis (155 ± 39; 135 ± 36; 103 ± 22; 77 ± 24 U/mL, respectively; P < 0.001). Conclusion: In this study, we showed that low PON1 activity is associated with the PON1 192RR genotypes and associated with the severity of CAD in the Tunisian population. We hypothesize that high level of Hcy together with low PON1 activity results in an increased plasma HcyT plasma concentration leading to protein N-homocysteinylation and the development and progression of atherosclerosis. © 2006 The Canadian Society of Clinical Chemists.